单中心大样本Epstein-Barr病毒相关性胃癌亚型的临床病理及分子特征分析

杨阳; 刘毅强; 王晓红; 季科; 李忠武; 白健; 杨爱蓉; 胡颖; 韩海勃; 李子禹; 步召德; 吴晓江; 张连海; 季加孚

doi:10.19723/j.issn.1671-167X.2019.03.012

北京大学学报（医学版） >

2019 , Vol. 51 >Issue 3: 451 - 458

DOI: https://doi.org/10.19723/j.issn.1671-167X.2019.03.012

论著

单中心大样本Epstein-Barr病毒相关性胃癌亚型的临床病理及分子特征分析

杨阳 ,
刘毅强 ,
王晓红 ,
季科 ,
李忠武 ,
白健 ,
杨爱蓉 ,
胡颖 ,
韩海勃 ,
李子禹 ,
步召德 ,
吴晓江 ,
张连海 ,
季加孚

展开

北京大学肿瘤医院暨北京市肿瘤防治研究所,恶性肿瘤发病机制及转化研究教育部重点实验室, 1. 胃肠肿瘤中心
^2. 病理科
^3. 生物样本库, 北京 100142
^4. 和瑞基因科技有限公司,北京 102206

季加孚,教授、主任医师、博士生导师、国务院特殊津贴专家。现任北京大学肿瘤医院、北京大学临床肿瘤学院院长,北京市肿瘤防治研究所所长,教育部恶性肿瘤发病机制及转化重点实验室主任,北京大学肿瘤研究中心主任。
兼任国际胃癌学会(International Gastric Cancer Association, IGCA)主席,中国抗癌协会副理事长,中国抗癌协会医院管理分会主任委员,中国医疗保健国际交流促进会副会长,中华医学会常务理事,中华医学会外科学分会常务委员兼秘书长,中国医师协会外科医师分会肿瘤外科医师委员会主任委员,约翰·霍普金斯大学医学院兼职教授,美国外科学院院士(Fellow of American College of Surgeons,FACS),英国皇家外科学院院士(Fellow of Royal Colleges of Surgeons, FRCS),亚洲外科学会(Asian Surgical Association,ASA)常务委员,中国人民政治协商会议第十三届全国委员会委员,中国民主同盟中央常务委员,中国民主同盟中央卫生与健康委员会主任。
从事医教研一线工作36年,在领导实现胃癌外科手术共识、创新围手术期治疗模式、率先建立胃癌样本库、探索个体化治疗分子机制等方面做出重要贡献。以第一或通信作者在Nature Communications、Annals of Oncology、Clinical Cancer Research等杂志发表SCI论文127篇,主编国内首个SCI收录的肿瘤学期刊。以第一完成人获国家科技进步二等奖1项、省部级一等奖3项,获吴阶平-保罗·杨森医学药学奖及英国文化教育协会职业成就奖,是国家卫生健康委员会突出贡献专家、北京学者。

收稿日期: 2019-03-18

网络出版日期: 2019-06-26

基金资助

国家自然科学基金(81502643)

收起

Clinicopathological and molecular characteristics of Epstein-Barr virus associated gastric cancer: a single center large sample case investigation

Yang YANG ,
Yi-qiang LIU ,
Xiao-hong WANG ,
Ke JI ,
Zhong-wu LI ,
Jian BAI ,
Ai-rong YANG ,
Ying HU ,
Hai-bo HAN ,
Zi-yu LI ,
Zhao-de BU ,
Xiao-jiang WU ,
Lian-hai ZHANG ,
Jia-fu JI

Expand

^1. Department of Gastrointestinal Cancer Center
^2. Department of Pathology
^3. Department of Biobank, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education; Laboratory of Genetics, Peking University Cancer Hospital & Institute, Beijing 100142, China
^4. Berry Oncology Corporation, Beijing 102206, China

Received date: 2019-03-18

Online published: 2019-06-26

Supported by

Supported by the National Natural Science Foundation of China(81502643)

Fold

摘要

目的 Epstein-Barr病毒相关性胃癌(Epstein-Barr virus associated gastric cancer, EBVaGC)与常见胃癌(非Epstein-Barr病毒相关性胃癌,Epstein-Barr virus non-associated gastric cancer, EBVnGC)不同,具有独特的临床病理特征,本研究采用单中心大样本探讨中国EBVaGC的临床病理及分子特征。方法回顾分析2003—2018年北京大学肿瘤医院EBVaGC与EBVnGC两组患者的临床病理特征和预后。分析公共数据库胃癌数据集,筛选显著差异表达基因,并在本组病例中验证重要基因的表达及其与预后的相关性。结果 3 241例胃癌患者纳入研究,EBVaGC为163例,占总数的5.0%。与EBVnGC相比,EBVaGC男性常见,平均年龄低,多见于残胃癌,常为低分化腺癌、Lauren混合型,较少出现淋巴结转移,EBVaGC患者的5年生存率为63.2%,优于EBVnGC的59.6%(P<0.05)。为挖掘EBVaGC的分子特征,对癌症基因组图谱(The Cancer Genome Atlas, TCGA)胃癌数据集(n=240)进行分析,筛选到7 404个显著差异表达基因,涉及细胞增殖、凋亡、侵袭转移等功能,其中侵袭转移相关基因SALL4下调、免疫检查点相关基因PD-L1上调是EBVaGC重要的分子特征。大样本验证显示,SALL4在EBVaGC中多为阴性(1/92,1.1%,低于EBVnGC的303/1 727,17.5%),PD-L1在EBVaGC中多为阳性(81/110,73.6%,高于EBVnGC的649/2 350,27.6%),SALL4阴性和PD-L1阳性患者的预后较好。结论 EBVaGC作为独特的胃癌亚型,较少出现转移且预后良好,该亚型具有特征性分子背景,其中侵袭转移相关基因SALL4的下调以及免疫检查点相关基因PD-L1的上调是重要的分子特征。

关键词： Epstein-Barr病毒感染; 胃肿瘤; 临床病理特征; 预后

本文引用格式

杨阳 , 刘毅强 , 王晓红 , 季科 , 李忠武 , 白健 , 杨爱蓉 , 胡颖 , 韩海勃 , 李子禹 , 步召德 , 吴晓江 , 张连海 , 季加孚 . 单中心大样本Epstein-Barr病毒相关性胃癌亚型的临床病理及分子特征分析[J]. 北京大学学报（医学版）, 2019 , 51(3) : 451 -458 . DOI: 10.19723/j.issn.1671-167X.2019.03.012

Abstract

Objective: Epstein-Barr virus associated gastric cancer (EBVaGC) is different from the traditional gastric cancer (Epstein-Barr virus non-associated gastric cancer, EBVnGC), and has unique clinicopathological features. This study investigated the largest single center cancer series so as to establish the clinicopathological and molecular characteristics of EBVaGC in China.Methods: A retrospective analysis was conducted on EBVaGC and EBVnGC patients diagnosed at Peking University Cancer Hospital from 2003 to 2018 by comparing their clinicopathological features and prognosis. The gastric cancer (GC) dataset of public database was analyzed to obtain differentially expressed genes. The expression of important genes and their association with prognosis of GC were verified in GC tissues from our hospital. Results: In this study, 3 241 GC patients were included, and a total of 163 EBVaGC (5.0%) patients were identified. Compared with EBVnGC, EBVaGC was higher in male and younger patients, and positively associated with remnant GC, poorly differentiated adenocarcinoma, and mixed type GC. EBVaGC was inversely related to lymph node metastasis. The 5-year survival rate of EBVnGC and EBVaGC was 59.6% and 63.2% respectively (P<0.05). In order to explore molecular features of EBVaGC, the Cancer Genome Atlas (TCGA) dataset was analyzed (n=240), and 7 404 significant differentially expressed genes were obtained, involving cell proliferation, apoptosis, invasion and metastasis. The down-regulated invasion/metastasis gene SALL4 and the up-regulated immune checkpoint gene PD-L1 were important molecular features of EBVaGC. Validation of these two genes in large GC series showed that the majority of the EBVaGC was SALL4 negative (1/92, 1.1%, lower than EBVnGC, 303/1 727, 17.5%), and that PD-L1 was mostly positive in EBVaGC (81/110, 73.6%, higher than EBVnGC, 649/2 350, 27.6%). GC patients with SALL4 negative and PD-L1 positive were often associated with better prognosis.Conclusion: EBVaGC is a unique subtype of GC with less metastasis and a good prognosis. It also has a distinct molecular background. The down-regulation of invasion/metastasis gene SALL4 and up-regulation of immune checkpoint gene PD-L1 are important molecular features.

Key words： Epstein-Barr virus infections; Stomach neoplasms; Clinicopathological features; Prognosis

参考文献

[1]	Horiuchi K, Mishima K, Ohsawa M , et al. Carcinoma of stomach and breast with lymphoid stroma: localisation of Epstein-Barr virus[J]. J Clin Pathol, 1994,47(6):538-540.
[2]	Network CGAR . Comprehensive molecular characterization of gastric adenocarcinoma[J]. Nature, 2014,513(7517):202.
[3]	Baek DW, Kang BW, Hwang S , et al. Clinical significance of p53 protein expression, beta-catenin expression and HER2 expression for Epstein-Barr virus-associated gastric cancer[J]. Chonnam Med J, 2017,53(2):140-146.
[4]	Camargo MC, Kim WH, Chiaravalli AM , et al. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis[J]. Gut, 2014,63(2):236-243.
[5]	Camargo M, Murphy G, Koriyama C , et al. Determinants of Epstein-Barr virus-positive gastric cancer: an international pooled analysis[J]. Brit J Cancer, 2011,105(1):38.
[6]	Murphy G, Pfeiffer R, Camargo MC , et al. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location[J]. Gastroenterology, 2009,137(3):824-833.
[7]	Dong M, Wang HY, Zhao XX , et al. Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma[J]. Hum Pathol, 2016,53:25-34.
[8]	Myers RB, Kudlow JE, Grizzle WE . Expression of transforming growth factor-alpha, epidermal growth factor and the epidermal growth factor receptor in adenocarcinoma of the prostate and benign prostatic hyperplasia[J]. Mod Pathol, 1993,6(6):733-737.
[9]	Yong KJ, Gao C, Lim JS , et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma[J]. N Engl J Med, 2013,368(24):2266-2276.
[10]	Harn HJ, Chang JY, Wang MW , et al. Epstein-Barr virus-asso-ciated gastric adenocarcinoma in Taiwan[J]. Hum Pathol, 1995,26(3):267-271.
[11]	Qiu K, Tomita Y, Hashimoto M , et al. Epstein-Barr virus in gastric carcinoma in Suzhou, China and Osaka, Japan: Association with clinico-pathologic factors and HLA-subtype[J]. Int J Can-cer, 1997,71(2):155-158.
[12]	Liu S, Zhao Z, Han L , et al. Epstein-Barr virus infection in gastric remnant carcinoma and recurrent gastric carcinoma in Qingdao of Northern China[J]. PLoS One, 2016,11(2):e0148342.
[13]	Sukawa Y, Yamamoto H, Nosho K , et al. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer[J]. World J Gastroenterol, 2012,18(45):6577-6586.
[14]	Kaizaki Y, Hosokawa O, Sakurai S , et al. Epstein-Barr virus-associated gastric carcinoma in the remnant stomach: de novo and metachronous gastric remnant carcinoma[J]. J Gastroenterol, 2005,40(6):570-577.
[15]	Zhang L, Xu Z, Xu X , et al. SALL4, a novel marker for human gastric carcinogenesis and metastasis[J]. Oncogene, 2014,33(48):5491-5500.
[16]	Kim ST, Cristescu R, Bass AJ , et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metasta-tic gastric cancer[J]. Nat Med, 2018,24(9):1449-1458.

Options

文章导航

模态框（Modal）标题

摘要

本文引用格式

Abstract

参考文献